智飞生物(300122) - 2016 Q1 - 季度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders of between 62.02 million and 76.33 million yuan, representing a year-on-year increase of 30% to 60%[2] - The company's net profit, after deducting non-recurring gains and losses, is also expected to rise by 30% to 60%[4] - The overall performance has improved compared to the same period last year, despite a decline in total operating income due to the change in product sales structure[3] - The performance forecast is based on preliminary estimates by the company's finance department and carries a degree of uncertainty[4] - The company emphasizes that non-recurring gains and losses have a minimal impact on its performance[4] Sales and Marketing - The sales structure has shifted towards more self-developed products, leading to an increase in sales revenue from these products, while agency product sales have decreased[3] - The marketing efforts for the AC-Hib combination vaccine have been strengthened, contributing to the growth in self-developed product sales[3] Investor Guidance - The financial data will be detailed in the first quarter report of 2016, and investors are advised to pay attention to investment risks[4]